Selecta Biosciences, Inc. and Sanofi announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Nano Vaccine immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes.

This collaborative research program is aimed at accelerating the advancement of an immunotherapy designed to reset the immune system and restore tolerance to substances (antigens) that cause the immune attacks on insulin-producing cells in the pancreas,  ИТАР-ТАСС reports.